Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.contributor | Univ Texas MD Anderson Canc Ctr | - |
Autor(es): dc.contributor | Universidade de São Paulo (USP) | - |
Autor(es): dc.contributor | Universidade Estadual Paulista (Unesp) | - |
Autor(es): dc.contributor | AC Camargo Canc Ctr | - |
Autor(es): dc.contributor | Inst Canc Sao Paulo | - |
Autor(es): dc.creator | Parra, Edwin Roger | - |
Autor(es): dc.creator | Jiang, Mei | - |
Autor(es): dc.creator | Machado-Rugolo, Juliana | - |
Autor(es): dc.creator | Yaegashi, Lygia Bertalha | - |
Autor(es): dc.creator | Prieto, Tabatha | - |
Autor(es): dc.creator | Farhat, Cecilia | - |
Autor(es): dc.creator | Sa, Vanessa Karen de [UNESP] | - |
Autor(es): dc.creator | Nagai, Maria Aparecida [UNESP] | - |
Autor(es): dc.creator | Cordeiro de Lima, Vladmir Claudio | - |
Autor(es): dc.creator | Takagaki, Tereza | - |
Autor(es): dc.creator | Terra, Ricardo | - |
Autor(es): dc.creator | Fabro, Alexandre Todorovic | - |
Autor(es): dc.creator | Capelozzi, Vera Luiza | - |
Data de aceite: dc.date.accessioned | 2022-02-22T00:56:52Z | - |
Data de disponibilização: dc.date.available | 2022-02-22T00:56:52Z | - |
Data de envio: dc.date.issued | 2021-06-25 | - |
Data de envio: dc.date.issued | 2021-06-25 | - |
Data de envio: dc.date.issued | 2020-10-01 | - |
Fonte completa do material: dc.identifier | http://dx.doi.org/10.5858/arpa.2019-0419-OA | - |
Fonte completa do material: dc.identifier | http://hdl.handle.net/11449/209539 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/11449/209539 | - |
Descrição: dc.description | Context.-Identification of gene mutations that are indicative of epithelial-mesenchymal transition and a noninflammatory immune phenotype may be important for predicting response to immune checkpoint inhibitors. Objective.-To evaluate the utility of multiplex immunofluorescence for immune profiling and to determine the relationships among tumor immune checkpoint and epithelial-mesenchymal transition genomic profiles and the clinical outcomes of patients with nonmetastatic non-small cell lung cancer. Design.-Tissue microarrays containing 164 primary tumor specimens from patients with stages I to IIIA non-small cell lung carcinoma were examined by multiplex immunofluorescence and image analysis to determine the expression of programmed death ligand-1 (PD-L1) on malignant cells, CD68; macrophages, and cells expressing the immune markers CD3, CD8, CD57, CD45RO, FOXP3, PD-1, and CD20. Immune phenotype data were tested for correlations with clinicopathologic characteristics, somatic and germline genetic variants, and outcome. Results.-A high percentage of PD-L1(+) malignant cells was associated with clinicopathologic characteristics, and high density of CD3+PD-1(+) T cells was associated with metastasis, suggesting that these phenotypes may be clinically useful to identify patients who will likely benefit from immunotherapy. We also found that ZEB2 mutations were a proxy for immunologic ignorance and immune tolerance microenvironments and may predict response to checkpoint inhibitors. A multivariate Cox regression model predicted a lower risk of death for patients with a high density of CD3(+)CD45RO(+) memory T cells, carriers of allele G of CTLA4 variant rs231775, and those whose tumors do not have ZEB2 mutations. Conclusions.-Genetic variants in epithelial mesenchymal transition and immune checkpoint genes are associated with immune cell profiles and may predict patient outcomes and response to immune checkpoint blockade. | - |
Descrição: dc.description | University of Texas Lung Cancer Specialized Programs of Research Excellence | - |
Descrição: dc.description | Foundation for the Support of Research of the State of Sao Paulo | - |
Descrição: dc.description | Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 1515 Holcombe Blvd,Unit 951, Houston, TX 77030 USA | - |
Descrição: dc.description | Univ Sao Paulo, Fac Med, Dept Pathol & Lab Genom & Histomorphometry, Sao Paulo, SP, Brazil | - |
Descrição: dc.description | Univ Sao Paulo, Fac Med, Div Pneumol, Heart Inst Incor, Sao Paulo, Brazil | - |
Descrição: dc.description | Sao Paulo State Univ, Clin Hosp, Fac Med, Dept Oncol, Sao Paulo, Brazil | - |
Descrição: dc.description | AC Camargo Canc Ctr, Med Oncol Dept, Sa Paulo, Brazil | - |
Descrição: dc.description | AC Camargo Canc Ctr, Translat Immune Oncol Grp, Sa Paulo, Brazil | - |
Descrição: dc.description | Inst Canc Sao Paulo, Dept Thorac Surg, Sao Paulo, Brazil | - |
Descrição: dc.description | Heart Inst Incor, Dept Thorac Surg, Sao Paulo, Brazil | - |
Descrição: dc.description | Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Pathol & Legal Med, Ribeirao Preto, Brazil | - |
Descrição: dc.description | Sao Paulo State Univ, Clin Hosp, Fac Med, Dept Oncol, Sao Paulo, Brazil | - |
Descrição: dc.description | University of Texas Lung Cancer Specialized Programs of Research Excellence: P50CA70907 | - |
Descrição: dc.description | Foundation for the Support of Research of the State of Sao Paulo: FAPESP 2013/14277-4 | - |
Descrição: dc.description | Foundation for the Support of Research of the State of Sao Paulo: FAPESP 2018-20403-6 | - |
Formato: dc.format | 1234-1244 | - |
Idioma: dc.language | en | - |
Publicador: dc.publisher | Coll Amer Pathologists | - |
Relação: dc.relation | Archives Of Pathology & Laboratory Medicine | - |
???dc.source???: dc.source | Web of Science | - |
Título: dc.title | Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer | - |
Tipo de arquivo: dc.type | livro digital | - |
Aparece nas coleções: | Repositório Institucional - Unesp |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: